SG | Jotup

Sweetgreen, Inc. Announces First Quarter 2024 Financial Results

Retrieved on:

Thursday, May 9, 2024

Retail, Restaurant, Bar, Food, Beverage, Economy, Depreciation, Webcast, Entrepreneurship, IPO, Acquisition, Coronavirus, Marketing, Adjustment, Advertising, GAAP, Growth, ERC, Pharmaceutical industry

Sweetgreen, Inc. (NYSE: SG) (the “Company”), the mission-driven, next generation restaurant and lifestyle brand that serves healthy food at scale, today announced financial results for its first fiscal quarter ended March 31, 2024.

Key Points:

Sweetgreen, Inc. (NYSE: SG) (the “Company”), the mission-driven, next generation restaurant and lifestyle brand that serves healthy food at scale, today announced financial results for its first fiscal quarter ended March 31, 2024.
For the first quarter of fiscal year 2024, compared to the first quarter of fiscal year 2023:
Total revenue was $157.9 million, versus $125.1 million in the prior year period, an increase of 26%.
For fiscal year 2024, we are updating our financial guidance to reflect the strength of the first quarter.
Sweetgreen will host a conference call to discuss its financial results and financial outlook today, May 9, 2024, at 2:00 p.m. Pacific Time.

Arcadia Biosciences (RKDA) Announces First Quarter 2024 Financial Results and Business Highlights

Retrieved on:

Thursday, May 9, 2024

Food, Beverage, Other Health, Health, Retail, Fitness & Nutrition, Form, Marketing, Bank statement, Zola

Reclassifications are related to the presentation of the financial results of our former body care brands as discontinued operations.

Key Points:

Reclassifications are related to the presentation of the financial results of our former body care brands as discontinued operations.
The financial information above and narrative that follows relate to continuing operations unless stated otherwise.
More detailed financial statements are included in the Form 8-K filed today, available in the Investors section of the company’s website under SEC Filings .
Revenues increased slightly during the first quarter of 2024 compared to the same period in 2023 driven by GoodWheat and Zola sales, partially offset by higher costs associated with new distribution.

Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update

Retrieved on:

Thursday, May 9, 2024

Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Key Points:

Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.
Research and development (R&D) expenses for the first quarter ended March 31, 2024 were $14.4 million compared to $17.5 million for the same period in 2023.
Total operating expenses for the first quarter ended March 31, 2024 were $98.8 million compared to $92.5 million for the same period in 2023.
ET on May 9, 2024 to discuss its financial results and provide a corporate update.

EQS-News: Wacker Neuson Group: As expected, first quarter of 2024 weaker than previous year – full-year revenue and EBIT guidance confirmed

Retrieved on:

Friday, May 10, 2024

Sale, PP, Investment, Uncertainty, Inventory, EUR, Tax, Growth

High dealer inventories are also leading to a weaker order intake and make it more difficult to reduce net working capital.

Key Points:

High dealer inventories are also leading to a weaker order intake and make it more difficult to reduce net working capital.
Revenue fell by 11.1 percent year-over-year to EUR 593.1 million (Q1 2023: EUR 667.2 million), while earnings before interest and taxes (EBIT) amounted to EUR 36.9 million (Q1 2023: EUR 87.8 million).
“After a very successful previous year, the 2024 financial year has begun with the expected challenges.
EBIT increases compared to Q4 2023: As expected, the EBIT margin improved compared to the previous quarter, reaching 6.2 percent.

AMN Healthcare Announces First Quarter 2024 Results

Retrieved on:

Thursday, May 9, 2024

VMS, Travel, School, Nursing, Public expenditure, Environment, Acquisition, EPS, AMN, Interim, MSDR, Growth, Video game

DALLAS, May 09, 2024 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its first quarter 2024 financial results. Financial highlights are as follows:

Key Points:

First quarter revenue was in line with expectations with all business segments in line with or slightly better than expectations.
AMN made progress in the first quarter, with year-over-year volume growth in language services, allied therapy, imaging and schools, and stabilizing trends in interim leadership.
Adjusted diluted EPS in the first quarter was $0.97 compared with $2.49 in the same quarter a year ago.
Our physician and leadership search businesses saw revenue decline by 29% year over year and 12% quarter over quarter.

Cibus Reports First Quarter Financial Results and Provides Business Update

Retrieved on:

Thursday, May 9, 2024

Corporation, Seed, WOSR, General counsel, Breeding, Research, CBUS, GMO, European Parliament, Carbon, Farmer, Entrepreneurship, PSR, HT1, Environment, Regeneration, HT2, SAN, Agriculture

"In the first quarter, we signed three agreements for Rice across North and Latin America.

Key Points:

"In the first quarter, we signed three agreements for Rice across North and Latin America.
Royalty liability interest expense - related parties: Royalty liability interest expense - related parties was $8.3 million for the quarter ended March 31, 2024.
Net loss: Net loss was $27.0 million for the quarter ended March 31, 2024, compared to $5.4 million in the year-ago period.
Cibus will host a live webcast, Thursday, May 9, 2024, at 4:30 p.m. Eastern Time to discuss its first quarter 2024 financial results and provide a business update.

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on:

Thursday, May 9, 2024

FDA, CMS, Risk, SARS-CoV-2, Food, Webcast, U.S. FDA, Administration, Research and development, Pre-exposure prophylaxis, COVID-19, Patient, Immunodeficiency, Medicine, Medicare, Clinical trial, HCPCS, Vaccine

“The recent months have been incredibly productive for Invivyd.

Key Points:

“The recent months have been incredibly productive for Invivyd.
At the beginning of April, Invivyd announced that PEMGARDA is available for purchase in the U.S. through a network of authorized specialty distributors.
The company will begin reporting PEMGARDA net product revenue with its second quarter 2024 financial results.
First Quarter 2024 Financial Results:
Cash Position: Cash and cash equivalents were $189.4 million as of March 31, 2024.

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on:

Thursday, May 9, 2024

REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2024 and recent business highlights:

Key Points:

Total unit demand grew 36% in Q1 2024 compared to Q4 2023 and represented a 108% increase compared to Q1 2023.
Based on data from IQVIA, UDENYCA franchise market share for Q1 2024 was 25%, an increase of 10 market share points in Q1 2024 compared to Q4 2023.
LOQTORZI, the first and only FDA-approved treatment for recurrent, locally advanced or metastatic NPC, commercially launched on January 2, 2024.
Coherus projects combined R&D and SG&A expenses for 2024 to be in the range of $250 to $265 million.

Galaxis Unleashed: The Highly Anticipated Token Launch on Bybit

Retrieved on:

Thursday, May 9, 2024

Bitcoin, Personality, Binance, Ecosystem, UTC, LaMelo Ball, News, Non-fungible token, NBA, NFT, Community, ETH, Cryptocurrency

Zurich, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- On the 10th of May 2024 at 10AM UTC, Galaxis, a Swiss-based Web3 platform, is set to announce its initial token launch, which will be accessible through the Bybit exchange platform.

Key Points:

Zurich, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- On the 10th of May 2024 at 10AM UTC, Galaxis, a Swiss-based Web3 platform, is set to announce its initial token launch, which will be accessible through the Bybit exchange platform.
Along the journey, partnerships with high-profile individuals like DJ Steve Aoki, actor Val Kilmer, and NBA personality LaMelo Ball have been established.
Incubated by CoinMarketCap, Galaxis enables individuals or brands with a community to create engagement and incentive mechanisms for their communities through NFTs.
For more information, refer to the official channels of Galaxis and Bybit .

Advantage Solutions Reports First Quarter Results with New Reporting Segments and Reaffirms its 2024 Outlook

Retrieved on:

Thursday, May 9, 2024

Sale, EDT, Investment, Capital expenditure, Easter, Public expenditure, Advantage, Adjustment, Growth

Excluding pass-through costs in 1Q’24 and 1Q’23 of approximately $85 million and $69 million, respectively, the year-over-year revenue growth was approximately 20%.

Key Points:

Excluding pass-through costs in 1Q’24 and 1Q’23 of approximately $85 million and $69 million, respectively, the year-over-year revenue growth was approximately 20%.
As part of that process, Advantage Solutions announced the sale of Adlucent, a performance media agency, to BarkleyOKRP.
Management reaffirms its outlook for 2024 with revenues and Adjusted EBITDA growth in the range of low single digits, excluding the in-year impact of the completed divestitures on the 2023 results.
Advantage will host a conference call at 8:30 am EDT on May 9, 2024 to discuss its first quarter 2024 financial performance and business outlook.